Novo Nordisk's shares fell sharply after disappointing results from CagriSema's clinical trials, raising concerns about its future in the competitive weight-loss market.
Recent studies reveal significant findings about dementia, including the potential benefits of caffeine and the risks posed by urinary tract infections in older adults.